Santen Pharmaceutical Co., Ltd.
SNPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.53B
Close$
$14.04
27.6% upside
Current Fair Value
27.6% upsideUndervalued by 27.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.53 Billion |
|---|---|
| Enterprise Value | $-43,374,512,131.00 |
| Annual dividend | $0.25 |
| Dividend yield | 2.31% |
| Earnings per Share | $115.04 |
| Beta | 0.24 |
| Outstanding Shares | 321,344,079 |
Return
| Return on Equity | 13.03% |
|---|---|
| Return on Assets | 9.41% |
| Return on Invested Capital | 13.93% |
Valuation & Multiples
| P/E Ratio | 14.56 |
|---|---|
| PEG | 67.71 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.74 |
| Enterprise Value to EBIT | 10.92 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.13
Consensus analyst estimateRevenue Estimate
$432.79 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.20
Consensus analyst estimateRevenue Estimate
$462.47 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Santen Pharmaceutical Co., Ltd.
3,968 employees
CEO: Takeshi Ito
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addr...